Micro Developing Active

Eli Lilly espande l'accesso a Zepbound per la crescita a lungo termine

Punteggio
0,5
Velocità
▲ 0,0
Articoli
9
Fonti
4

Riepilogo

Un articolo appartiene a questa narrazione se discute l'espansione dell'accesso a Zepbound da parte di Eli Lilly e le sue prospettive di crescita a lungo termine.

Articoli Correlati

Jim Cramer Likes Eli Lilly’s (LLY) New Deal

Yahoo Finance · Apr 05, 2026
Mixed

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Nasdaq · Apr 04, 2026
Mixed

Eli Lilly secures long-awaited FDA approval for its obesity pill. Here's what to know

CNBC · Apr 01, 2026
Mixed

The cutthroat battle for the US weight-loss drug market

BBC Business · Mar 23, 2026
Mixed

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook

Yahoo Finance · Mar 22, 2026
Mixed

Fonti

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of … Nasdaq
Jim Cramer Likes Eli Lilly’s (LLY) New Deal Yahoo Finance
Is Eli Lilly and Company (LLY) The Best Pharma Stock … Yahoo Finance
Eli Lilly secures long-awaited FDA approval for its obesity pill. … CNBC
Eli Lilly reaches $2.75 billion deal with Insilico to bring … CNBC
Here's How Much Upside Eli Lilly Stock Has, According to … Yahoo Finance
The cutthroat battle for the US weight-loss drug market BBC Business
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing … Yahoo Finance

Cronologia

Ultimo aggiornamento Mar 22, 2026